The results of this study showed that administration of AAV5-hNR2E3 at any of the three doses evaluated resulted in sustained attenuation of retinal degeneration over 6 months when administered during early or intermediate progression of rd7 retinal degeneration. Here, NR2E3 is linked to retinal degeneration.